Industry Background: Why Global Biopharma Needs a China Microbial CRDMO for Global Regulatory Compliance Biopharmaceutical developers pursuing simultaneous approvals in the United States, China, Europe, and Australia face a layered set of obstacles. Mammalian expression systems, long the default for recombinant biologics, are frequently constrained by low yields and stability issues, while...